Key result
Vitamin K antagonist use in patients with atrial fibrillation was associated with a pooled major bleeding rate of 2.51 bleeds per 100 patient-years (99% CI: 2.03-3.11).
Systematic Review (n=342,699)
The pooled rate of major bleeding in atrial fibrillation patients taking vitamin K antagonists is 2.51 per 100 patient-years, providing a robust baseline estimate for clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Supports individualized bleeding risk counseling in AF patients on VKAs; extends literature with a contemporary pooled estimate.
Lopes et al. (2013) conducted a systematic review in Atrial Fibrillation (n=342,699). Vitamin K antagonists (VKAs) was evaluated on Major bleeding rate (95% CI 2.03-3.11). Vitamin K antagonist use in patients with atrial fibrillation was associated with a pooled major bleeding rate of 2.51 bleeds per 100 patient-years (99% CI: 2.03-3.11).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: